ECR 2015

Mar 4, 2015

Classical meets modern: The Red Bull Flying Steps performs during the opening ceremony of ECR 2015 on Wednesday.

none
Latest in Conference
Conference hall with attendees seated facing a large blue projection screen displaying Vienna event branding and architectural imagery
EANM: AI studies target tumor boards, PET/CT protocoling, and PD-L1 prediction
October 20, 2026
A26 NMM World Leading Meeting event branding displayed over an aerial cityscape at sunset
EANM: Lu-177 edotreotide dose linked to tumor response
October 20, 2026
A26 NMM World Leading Meeting event branding overlay on aerial city skyline at sunset
EANM: New PET tracer shows promise in kidney cancer
October 20, 2026
Formal event on stage with elegantly dressed guests and musicians performing on large screen display above
EANM 2026 opened with Nobel lessons and waltz
October 19, 2026
Related Stories
2015 02 27 13 14 43 455 Ecr 2015 200
Conference
Tracking software tackles CT dose monitoring
2015 03 05 11 56 48 369 2015 03 05 Ecr Video Ranschaert
Conference
Video from ECR 2015: Dr. Erik Ranschaert on mobile IT
2015 02 27 13 14 43 455 Ecr 2015 200
Conference
Nodule volumes overestimated on diameter measurements
2015 03 05 10 56 13 610 2015 03 06 Ecr Video Hosten
Conference
Video from ECR 2015: Dr. Norbert Hosten on German radiology
More in Conference
EANM: AI studies target tumor boards, PET/CT protocoling, and PD-L1 prediction
By Claudia Tschabuschnig
A multi-agent AI system improved tumor board recommendations, while other studies explored PET/CT protocol selection and cancer biomarker prediction at EANM 2026 in Vienna.
October 20, 2026
Conference hall with attendees seated facing a large blue projection screen displaying Vienna event branding and architectural imagery
EANM: Lu-177 edotreotide dose linked to tumor response
By AuntMinnieEurope.com staff writers
Objective response rates climbed from 12% in the lowest dose quartile to 64% in the highest.
October 20, 2026
A26 NMM World Leading Meeting event branding displayed over an aerial cityscape at sunset
EANM: New PET tracer shows promise in kidney cancer
By Will Morton
Across 492 true lesions evaluated in the study, Ga-68 DPI-4452 PET/CT detected 90.9%, compared with 56.7% using F-18 FDG PET/CT.
October 20, 2026
A26 NMM World Leading Meeting event branding overlay on aerial city skyline at sunset
EANM 2026 opened with Nobel lessons and waltz
By Claudia Tschabuschnig
The opening ceremony of EANM 2026 combined scientific inspiration with a Viennese waltz.
October 19, 2026
Formal event on stage with elegantly dressed guests and musicians performing on large screen display above
Video from EANM: President Erba on radiopharmaceuticals, PET, and AI
By Claudia Tschabuschnig
Advances in radiopharmaceuticals, PET imaging, and AI are driving personalized nuclear medicine, according to EANM President Prof. Paola Anna Erba.
October 19, 2026
Woman wearing glasses and gray blazer speaking at a microphone during a professional conference or event
EANM 2026: How early is early enough in prevention?
By Claudia Tschabuschnig
Experts question whether PET-based screening is ready for cancer, heart disease, and Alzheimer’s, and what evidence would justify it.
October 19, 2026
Panel discussion at ISTAT26 conference in Vienna with speaker presenting on stage while seated panelists listen
EANM: Thomas Hope on what’s next in FAP-targeted theranostics
By Will Morton
The innovations and work being done to optimize FAP agents will likely "spill over" to other targets.
October 19, 2026
Clinical research presentation slide showing FAP RLT experience data table with patient outcomes across multiple institutions and speaker photo
EANM: Affibody presents data on HER2 radioligand therapy
By AuntMinnieEurope.com staff writers
The Stockholm, Sweden-based company is highlighting progress across its radiopharmaceutical pipeline.
October 19, 2026
A26 NMM World Leading Meeting event branding overlaid on aerial cityscape at sunset
EANM: Akiram presents first clinical data for CD44v6-targeted therapy
By AuntMinnieEurope.com staff writers
The first-in-human ongoing phase I trial is evaluating Lu-177 AKIR001 in patients with irresectable or metastatic CD44v6-positive solid tumors.
October 19, 2026
A26 NMM World Leading Meeting event branding overlaid on aerial cityscape at sunset
EANM: Next-generation PET scanner cuts imaging time to one minute
By Will Morton
The scanner's fastest images were rated more highly on average than those from a standard PET/CT scanner.
October 18, 2026
PET scan comparison showing SAFOV baseline and 1-minute and 5-minute time-point imaging with tracer uptake patterns
René Chapot challenges measures of success in distal thrombectomy
By Claudia Tschabuschnig
At neuroRAD 2026 in Mainz, Prof. Dr. René Chapot questioned in a video interview how success in distal thrombectomy is measured and explored the future of neurointervention.
October 16, 2026
Professional man in dark suit at medical conference with Ultravist product display in background
From theranostics to patient access: What to expect at EANM 2026
By Claudia Tschabuschnig
Around 10,000 participants from 138 countries are expected in Vienna as nuclear medicine expands its role in cancer treatment and molecular imaging.
October 15, 2026
LA26 NMM World Leading Meeting logo displayed over Vienna cityscape
Page 1 of 147
Next Page